

If you would like to refer a patient for a PSMA PET/CT scan, please complete this form and send it to SMIL, please also include the following to expedite schedule and authorization: Clinical Recent Imaging Reports 2 Most Recent PSA Results Script/Order

Please select an imaging agent: F-18 Pylarify Ga-68 PSMA-11 Illuccix Ga-68 PSMA-11 Locametz

Patient Name: _____ *Today's Date: _____

Patient DOB: _____ Patient Day Phone / Cell: _____

Secondary Insurance: _____ Subscriber ID: _____ Prior Auth#: _____

Secondary Insurance: _____ Subscriber ID: _____ Prior Auth#: _____

Specific Reason for PSMA PET Study

Initial Staging - for detection of suspected metastasis in patients with newly diagnosed prostate cancer who are candidates for initial definitive therapy.

*Please see NCCN guidelines for initial Risk Stratification and Staging Workup (below)

Unfavorable – Intermediate (check all that apply)

- cTaB-cT2c PSA 10-20
- Grade Group 3 ≥ 50% Positive Core Biopsies

High Risk

- cT3a PSA > 20
- Grade Group 4 or Grade Group 5

Very High Risk

- cT3b-cT4 Primary Gleason Pattern 5
- Grade Group 4 or Grade Group 5
- > 4 Cores with Grade Group 4 or 5

Suspected Recurrence - previously treated prostate cancer based on elevated PSA

Prior Treatment (check all that apply)

- Prostatectomy
- Radiation
- Chemotherapy
- ADT
- Other (specify): _____

Lab Work

PSA Nadir After Treatment: _____

Current PSA: _____

Date: _____

PSA Doubling Time (if applicable): _____

Signature of Provider verifying patient status above: _____

ICD-10 Code(s)

Code	Description
C61	Malignant neoplasm of prostate
Z79.82	Secondary malignant neoplasm of genital organ must be billed accompanied by C61
Z19.1	Hormone sensitive malignancy
Z19.2	Hormone resistant malignancy
Z85.46	Personal history of malignant neoplasm of prostate must be billed accompanied by C61
R97.21	Rising PSA following treatment for malignant neoplasm of prostate
Other	

NCCN Guidelines Version 1.2023 Prostate Cancer INITIAL RISK STRATIFICATION AND STAGING WORKUP FOR CLINICALLY LOCALIZED DISEASES

Risk Group	Clinical/Pathologic Features See Staging (ST-1)	Additional Evaluation ^{h,i}	Initial Therapy
Very low ^f	Has all of the following: • cT1c • Grade Group 1 • PSA <10 ng/mL • Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core ^g • PSA density <0.15 ng/mL/g	• Confirmatory testing can be used to assess the appropriateness of active surveillance (See PROS-F 2 of 5)	See PROS-3
Low ^f	Has all of the following but does not qualify for very low risk: • cT1-cT2a • Grade Group 1 • PSA <10 ng/mL	• Confirmatory testing can be used to assess the appropriateness of active surveillance (See PROS-F 2 of 5)	See PROS-4
Intermediate ^f	Has all of the following: • No high-risk group features • No very-high-risk group features • Has one or more intermediate risk factors (IRFs): ▶ cT2b-cT2c ▶ Grade Group 2 or 3 ▶ PSA 10-20 ng/mL	Favorable intermediate Has all of the following: • 1 IRF • Grade Group 1 or 2 • <50% biopsy cores positive (eg, <6 of 12 cores) ^g	• Confirmatory testing can be used to assess the appropriateness of active surveillance (See PROS-F 2 of 5) See PROS-5
		Unfavorable intermediate Has one or more of the following: • 2 or 3 IRFs • Grade Group 3 • ≤50% biopsy cores positive (eg, ≤6 of 12 cores) ^g	Bone and soft tissue imaging ^{ik} • If regional or distant metastases are found, see PROS-8 or PROS-12 See PROS-6
High	Has no very-high-risk features and has exactly one high-risk feature: • cT3a OR • Grade Group 4 or Grade Group 5 OR • PSA >20 ng/mL	Bone and soft tissue imaging ^{ik} • If regional or distant metastases are found, see PROS-8 or PROS-12	See PROS-7
Very high	Has at least one of the following: • cT3b-cT4 • Primary Gleason pattern 5 • 2 or 3 high-risk features • >4 cores with Grade Group 4 or 5	Bone and soft tissue imaging ^{ik} • If regional or distant metastases are found, see PROS-8 or PROS-12	See PROS-7